The AIM-PD trial (ambroxol)

Supported by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly. Phase ll of the ‘AIM-PD’ study was a proof of concept study and involved 20 people with the genetic form of Parkinson’s over a 24…


Clinical trials

The UP-Study trial (UDCA)

  This trial is now complete. Supported by Cure Parkinson’s and the J P Moulton Foundation, the results are expected in 2021. Originally used to treat cirrhosis of the liver, researchers found that the rescue effect of UDCA on the liver cells may actually be due…


News Clinical trials

The PD-STAT/Simvastatin study results

Why is this important? In 2012, an international committee of Parkinson’s experts brought together by Cure Parkinson’s prioritised simvastatin for clinical evaluation in Parkinson’s. The International Linked Clinical Trials (iLCT) committee believed that there was considerable supporting evidence indicating that this widely used medication may…


News Clinical trials

An overview of drug development for Parkinson’s

A recently published research report conducted by Parkinson’s research advocates and Cure Parkinson’s presents an encouraging overview of pipeline agents being clinically tested for Parkinson’s.


Ambroxol in Parkinson’s: results of phase 2 trial published

Background In late 2014, the International Linked Clinical Trials (iLCT) committee prioritised ambroxol for clinical evaluation in Parkinson’s after the preclinical data presented at the LCT meeting suggested that this drug was a promising candidate for drug repurposing. Ambroxol is a commonly used medication in Europe for the…